GloPID-R brings together funding bodies investing in research related to new or re-emerging infectious diseases. Our aim is to ensure that research capacity and capabilities are in place to support the rapid initiation of scientific research in case of an outbreak.
A framework is being developed as a basis for sharing data during public health emergencies. The data to be considered includes surveillance data, clinical trial data, pathogen genome data, case reports and results derived from this data. An action plan will be drawn up by the working group to identify areas where progress can be made quickly.
When an infectious disease emerges, GloPID-R members respond by developing funding calls that facilitate research being quickly conducted. The members voluntarily share with GloPID-R their open funding calls related to infectious diseases to be published on the website and in the newsletter.
research and reports
GloPID-R conducts a review and assessment on regarding the latest research on infectious diseases, including the Zika virus and Ebola.
GloPID-R also conducted a Connecting and Mapping Study to explore the capacities and capabilities of both research networks and funders to respond to outbreaks of pandemic potential. The report also explores the PEARLES (political, ethical, administrative, regulatory, logistical, economic, and social) barriers to rapid pandemic research in greater detail.
ZIKA outbreak response
On the same day as PAHO’s epidemiological alert (December 1, 2015) GloPID-R initiated its response to the Zika outbreak. Working groups were rapidly formed to address issues related to aetiology, vaccines, diagnostics and vector control. Their findings are available in the report, Ongoing and Upcoming Research on the Zika Virus. This regularly updated document identifies experts, research capacities in the field of ZIKV and key research questions. See also Zika Outbreak for a complete list of actions.
GloPID-R also mobilized its members to discuss the Yellow Fever outbreak in Angola and several other African countries where there was a risk of a temporary shortage of available vaccines. It developed a working group to identify research gaps and possible priorities.